Laboratorios Farmaceuticos Rovi, S.A.

Total Valuation

Laboratorios Farmaceuticos Rovi, S.A. carries a market capitalization of 3.44B, placing it among publicly traded companies globally. Its enterprise value stands at 4.05B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Laboratorios Farmaceuticos Rovi, S.A. currently has 51.14M shares outstanding.

Valuation Ratios

Laboratorios Farmaceuticos Rovi, S.A. trades at a trailing price-to-earnings ratio of 21.91. The price-to-sales ratio is 5.25, and the price-to-book ratio stands at 5.79.

Enterprise Valuation

On an enterprise value basis, Laboratorios Farmaceuticos Rovi, S.A. trades at an EV/EBITDA multiple of 23.07 and an EV/FCF ratio of 12.14. The EV/Sales ratio of 5.24 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 23.07 provides insight into valuation relative to core operating earnings.

Financial Position

Laboratorios Farmaceuticos Rovi, S.A. maintains a current ratio of 2.05, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.02, indicating elevated leverage, while an interest coverage ratio of 44.00 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Laboratorios Farmaceuticos Rovi, S.A. posts a return on equity of 29.30 and a return on invested capital of 17.70.

Taxes

Over the trailing twelve months, Laboratorios Farmaceuticos Rovi, S.A. has paid 50.17M in income taxes, reflecting an effective tax rate of 21.33.

Stock Price Statistics

Laboratorios Farmaceuticos Rovi, S.A.'s stock has declined approximately -25.86911% over the past 52 weeks. The 50-day moving average sits at 78.89, while the 200-day moving average is 87.68.

Income Statement

Over the trailing twelve months, Laboratorios Farmaceuticos Rovi, S.A. generated 773.05M in revenue and converted that into 185.18M in net income, yielding earnings per share of 3.62. EBITDA reached 175.62M, while operating income came in at 175.62M.

Balance Sheet

Laboratorios Farmaceuticos Rovi, S.A. holds 128.07M in cash and equivalents against 107.69M in total debt, resulting in a net debt position of -126.97M. Total book value stands at 700.62M, with working capital of 291.41M providing operational flexibility.

Cash Flow

Laboratorios Farmaceuticos Rovi, S.A. produced 253.32M in operating cash flow over the past twelve months. After subtracting -77.40M in capital expenditures, free cash flow totaled 175.92M - equivalent to 3.44 per share.

Margins

Laboratorios Farmaceuticos Rovi, S.A. operates with a gross margin of 66.17, reflecting its pricing power and cost economics. The operating margin of 22.72 and net profit margin of 23.95 provide insight into operational efficiency.

Dividends & Yields

Scores

Laboratorios Farmaceuticos Rovi, S.A. posts an Altman Z-Score of 8.28, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.